Debu Tripathy, MD,

Articles

Dr. Tripathy on Efforts to Minimize Risk of Recurrence in Early-Stage HER2+ Breast Cancer

March 5th 2021

Debu Tripathy, MD, discusses efforts being made to minimize the risk of disease recurrence in patients with early-stage HER2-positive breast cancer.

Dr. Tripathy on Updated Results of the MONALEESA-7 Trial in HR+/HER2- Breast Cancer

December 10th 2020

Debu Tripathy, MD, discusses updated results of the phase 3 MONALEESA-7 trial in hormone receptor–positive, HER2-negative breast cancer.

Dr. Tripathy on Treatment De-Escalation in HER2+ Breast Cancer

October 28th 2020

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers

August 10th 2020

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

Dr. Tripathy on Genomically Guided Therapy in Breast Cancer

July 31st 2020

Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.

Dr. Tripathy on Known Elements of COVID-19

March 21st 2020

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses known elements of COVID-19.

Dr. Tripathy on Personalized Therapy Options in Metastatic Breast Cancer

March 8th 2020

Debu Tripathy, MD, discusses personalized therapy options in metastatic breast cancer.

Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast Cancer

June 2nd 2019

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.

Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in Breast Cancer

March 9th 2019

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies being investigated with CDK4/6 inhibitors in breast cancer.

CDK4/6 Inhibitors Play a Growing Role in Enhancing Endocrine Therapy

March 9th 2019

For more than 100 years, endocrine therapy has been used for the treatment of breast cancer; since that time, we have learned much about the role of estrogen in the biology of normal breast cancer development.

Dr. Tripathy Discusses Impact of T-DM1 in HER2+ Breast Cancer

January 7th 2019

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of T-DM1 in HER2-positive breast cancer.

Dr. Tripathy Discusses Pertuzumab in HER2+ Breast Cancer

December 21st 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of pertuzumab in HER2-positive breast cancer.

Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in HR+ Breast Cancer

September 10th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies with CDK4/6 inhibitors for the treatment of patients with hormone receptor (HR)-positive breast cancer.

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast Cancer

August 23rd 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses frontline endocrine therapies for patients with hormone receptor (HR)-positive breast cancer.

Dr. Tripathy on the Progression of Biosimilars in Oncology

August 14th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the progression of biosimilars in oncology.

Dr. Tripathy on the Importance of Biosimilars in Oncology

July 26th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of biosimilars in oncology.

Dr. Tripathy on the Management of HR+ Early-Stage Breast Cancer

July 13th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of hormone-receptor (HR)-positive early-stage breast cancer.

Dr. Tripathy on Impact of Olaparib Approval in BRCA-Positive Breast Cancer

March 8th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of olaparib (Lynparza) for patients with BRCA-positive breast cancers and the impact it has had on clinical practice. Tripathy shared this insight in an interview during the 35th Annual Miami Breast Cancer Conference.

Dr. Tripathy Discusses Lurbinectedin in Breast Cancer

December 14th 2017

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses lurbinectedin (PM01183) for patients with breast cancer.

Dr. Tripathy Discusses Neratinib in HER2+ Breast Cancer

December 12th 2017

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.